{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T01:27:47Z","timestamp":1745198867478,"version":"3.37.3"},"reference-count":10,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,7]]},"DOI":"10.1182\/blood-2017-10-809673","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T12:30:29Z","timestamp":1512649829000},"page":"2447-2448","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["T-PLL: another check on the venetoclax list?"],"prefix":"10.1182","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"first","affiliation":[{"name":"UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina Y.","family":"Konopleva","sequence":"additional","affiliation":[{"name":"UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"23","key":"2019111903324478400_B1","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood-2017-05-785683","article-title":"First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia","volume":"130","author":"Boidol","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019111903324478400_B2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.hoc.2016.11.010","article-title":"T-cell prolymphocytic leukemia","volume":"31","author":"Sud","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"2019111903324478400_B3","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111903324478400_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111903324478400_B5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"9","key":"2019111903324478400_B6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2017-04-737338","article-title":"Targeting BCL-2 in B-cell lymphomas","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2019111903324478400_B7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"9","key":"2019111903324478400_B8","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"10","key":"2019111903324478400_B9","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"journal-title":"Leukemia","article-title":"Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling [published online ahead of print 14 August 2017]","author":"Andersson","key":"2019111903324478400_B10"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/23\/2447\/1404414\/blood809673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/23\/2447\/1404414\/blood809673.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:33:03Z","timestamp":1574134383000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/23\/2447\/36772\/TPLL-another-check-on-the-venetoclax-list"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":10,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,12,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-10-809673","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2017,12,7]]}}}